Acute Myeloid Leukemia, LYT-200 and Fast Track
PureTech Drug Gets FDA Fast-Track Designation for Leukemia
The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid leukemia, as well as a separate fast-track designation for the treatment of recurrent/metastatic head and neck squamous cell carcinomas.
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the U.
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
A young man has been diagnosed with acute stage 3 leukemia and urgently needs help to survive. He has appealed to the general ...
Hosted on MSN6h
How Is Leukemia Diagnosed?Medically reviewed by Doru Paul, MD Leukemia is a cancer of the blood-forming tissues that often develops in the bone marrow.
Researchers sought to determine if HRQoL measures differ with gilteritinib compared with placebo in patients with AML.
A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug ...
Interesting trends were observed in the subgroup analyses of the phase 3 uproleselan study in relapsed or refractory acute ...
A special blood drive was held Monday afternoon to honor a Cranston High School East teacher battling leukemia.
Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...
Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic ...
In a significant advancement for cancer research, a team of scientists from Max Planck Institute for Biology Tübingen, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback